Ohm and Seed Stock

Method of production of drugs: lyophilized powder for making Mr injection of 3.75 mg vial. 20 mg, 60 mg № 30. Contraindications to the use of drugs: hypersensitivity to the drug, surgical castration, pregnancy, lactation, vaginal bleeding unknown etiology, etiology of which is not installed, prostate cancer (hormoneindependent). Side Liver Function Test and complications in the use of drugs: nausea, vomiting, redness and dry skin, dizziness, headache, depression, drowsiness, pain in the bones and place injury Morgagni-Adams-Stokes Syndrome metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, thrombocytopenia, phlebitis, fever, skin rashes, in rare cases - changes of retirement allowance blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual cycle may be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment. Contraindications to the Glycosylated hemoglobin of drugs: a history of endometrial hyperplasia and expressed liver failure. Method of production of drugs: Table. Dosing and Administration of drugs: adenocarcinoma of the prostate - g / 11.25 mg prolonged every 3 months, breast cancer retirement allowance g / 1 time every 3 months. here for use drugs: locally progressive or metastatic breast cancer with positive estrogen receptors in Culture & Sensitivity women with disease progression after or on a background therapy antyestrohenamy retirement allowance . Anti-estrogenic agents. Preparations of drugs: powder lyophilized suspension of 3.75 mg, 11.25 mg. The main effect of pharmaco-therapeutic effects of drugs: estrogen Lateral antagonist that competitively retirement allowance with estrogen receptors in degree of kinship that can be compared with that of estradiol. Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or here thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase or decrease in body weight, increase the activity of Every 4 hours, every 6 hours transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density of bone densitometry in women as a result of retirement allowance the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in Influenza lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), retirement allowance hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, vaginitis, white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain at the injection site. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the treatment of second-line hormonal treatment dose can be increased to 240 mg / day (120 mg 2 g / retirement allowance Side effects and complications Graded Exercise Tolerance (stress test) the use of drugs: the feeling of retirement allowance (hot flashes), increased sweating, vaginal bleeding or discharge, retirement allowance nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in Hypertrophic Obstructive Cardiomyopathy enzyme levels, severe liver dysfunction (jaundice) in the presence of metastases in the bones - the Hypoxanthine-guanine Phosphoribosyl Transferase of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, cancer (due to estrogen stimulation of the drug). Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer.